The suffering of patients with incurable cancer is determined to a large degree by the presence and intensity of the symptoms of their disease. Knowledge of symptom prevalence is important for clinical practice. The main aim of this study was to obtain a reliable estimation of symptom prevalence in patients with incurable cancer by performing a systematic review of studies assessing this topic. We included 44 studies (including 25,074 patients) on overall symptom prevalence (Group 1) and six studies (including 2,219 patients) on symptom prevalence during the last one to two weeks of life (Group 2). In these studies, symptom prevalence was assessed by a questionnaire, a standardized interview, or the medical record. We identified 37 symptoms assessed in at least five studies. Almost all symptoms occurred in more than 10% of the patients. Five symptoms (fatigue, pain, lack of energy, weakness, and appetite loss) occurred in more than 50% of the patients of Group 1. Weight loss occurred significantly more often in Group 2 compared to Group 1, and pain, nausea, and urinary symptoms occurred significantly less often. Generally, symptom prevalence was highest if assessed by a questionnaire. The results of this study should be used to guide doctors and nurses in symptom management. Proper attention to symptom burden and suffering should be the basis for individually tailored treatment aimed at improving or maintaining quality of life of patients in their last period of life. J Pain Symptom Manage 2007;34:94e104.
Introduction
Palliation implies a shift from cure and control of the disease to improvement or maintenance of quality of life. This shift in focus is an essential event for cancer patients and their loved ones, and also for doctors and nurses. Physical symptoms, functional deficits, and feelings of loss of control become the focus of care. 1, 2 The World Health Organization has defined palliative care as ''an approach to care which improves quality of life of patients and their families facing life threatening illness through the prevention and relief of suffering by means of identification and impeccable assessment of pain and other problems, physical, psychosocial and spiritual.'' 3 The palliative phase has different dynamics in every patient. However, the suffering of these patients is determined to a large degree by the presence and intensity of the symptoms of their disease. Knowledge of symptom prevalence is important for clinical practice as it enables doctors and nurses to focus on the more prevalent symptoms and may help to anticipate problems and plan care for patients, to educate clinical staff, to direct assessments of health care need, and to plan services. 4 Many studies have addressed this issue in patients with incurable diseases, most often in those with cancer. However, these studies are heterogeneous with regard to patients and assessment method, and the numbers of patients included are often relatively low.
The main aim of this study was to obtain a reliable estimation of symptom prevalence in patients with incurable cancer by performing a systematic review of studies assessing this topic. Secondary aims were 1) to study differences in symptom prevalence during the last one to two weeks of life, and 2) to assess the influence of assessment method, gender, and age on symptom prevalence.
Methods

Literature Review
We performed a systematic literature review using the following databases: MEDLINE, EMBASE, and CINAHL. When papers were found, they were hand searched for crossreferences. To avoid problems concerning the meaning and categorization of symptoms, we included only papers in the English language. The data were primarily extracted by one of the authors (WW) and checked by two other authors (ST and AdG). These three authors decided how to categorize the symptoms (see Results).
Papers were excluded if they:
-were not describing original studies; -focused on only one specific symptom (e.g., fatigue, depression) without prevalence data on other symptoms;
-assessed symptoms by proxy; -gave only data on symptom intensity (without specifying the number or percentage of patients with or without the symptom); -included more than 10% of patients without cancer and did not supply data on symptom prevalence by diagnosis; -included patients with cancer before, during, or after curative treatment.
Symptoms were included in the analysis only if they were assessed in at least 10% of the studies.
Analysis
We separated studies assessing symptom prevalence in the last one to two weeks of life (Group 2) from other studies (Group 1). If symptoms were assessed at different time points in the same study, only the baseline data were used for Group 1. If the last assessment was done in the last one to two weeks of life, these data were also used for Group 2.
Obviously, the prevalence of a symptom could be determined only for those studies assessing that specific symptom. Each prevalence was first transformed to a log odds to better conform to a normal distribution. The Q-test was used to determine whether there was heterogeneity in the log odds of the various studies. Pooled log odds were then estimated using the random effects model, 5 and consequently back transformed, resulting in pooled prevalence estimates with 95% confidence intervals (CIs).
Nonparametric tests (Mann-Whitney, KruskallWallis) were used to detect differences in mean percentages between groups.
For statistical analysis, the Statistical Package for the Social Sciences, version 12.0 (SPSS, Inc., Chicago, IL) were used, and the statistical package R (R version 2.2.0, The R Development Core Team) with library ''meta'' Statistical significance was assumed if P < 0.05.
Results
We identified 46 studies that met the inclusion criteria, 6e55 including a total of 26,223 patients. Some papers 6, 7, 20, 21, 32, 33, 43, 44 referred to the same patient population. Data from 40 of these studies 6e53 were included for Group 1, data from four studies were included for both groups, 26,32e34,46 and data from two studies were included for Group 2 only. 54, 55 Patient characteristics are summarized in Table 1 . Group 1 included 25,074 patients, and Group 2 included 2,219 patients. Ten studies gave data on median or mean survival, which varied from 3 to 12 weeks. 16,23,31e33,35,37,41,43,44,48,52 As to be expected, symptoms were labeled differently in different studies. We categorized these symptoms (in the order of decreasing prevalence) as follows: fatigue (including tiredness), pain, lack of energy, weakness (asthenia), appetite loss (anorexia), nervousness, weight loss, dry mouth (xerostomia), depressed mood (depression, mood changes, feeling low, miserable, or sad), constipation, worrying, insomnia (inability to sleep, difficulty or problems sleeping, sleep problems or disturbances, sleeplessness, poor sleep), dyspnea (breathlessness, shortness of breath, trouble with breathing), nausea, anxiety (fearful), irritability, bloating, cough, cognitive symptoms (memory or concentrating problems, difficulty concentrating), early satiety, taste changes (unpleasant taste), sore mouth/ stomatitis (mouth sores or lesions, oral candida, oral or mouth discomfort, mucositis), vomiting (emesis), drowsiness (sleepiness, sedation), edema (swollen limb, lymphedema), urinary symptoms (dysuria, incontinence, problems with urination, loss of bladder control, bladder disturbances), dizziness, dysphagia (difficulty swallowing), confusion (disorientation), bleeding (hemorrhage), neurological symptoms (hemiplegia, paralysis, paresis, numbling/ tingling, paresthesias), hoarseness, dyspepsia (gastric discomfort), skin symptoms (pressure, wound or bed sores, dermatologic), diarrhea (loose stool), pruritus (itching), and hiccup.
For both groups, virtually all Q-tests for statistical heterogeneity were (very) significant, indicating a very high level of heterogeneity of the studies included in this review.
Symptom Prevalence in Group 1
In total, we identified 37 symptoms that were assessed in at least five (>10%) studies (range: 5e40) for Group 1. Almost all symptoms occurred in >10% of the patients (Table 2 23 or other questionnaires 9,11 ). Eighteen studies used a selfdeveloped standardized interview by a doctor or nurse, 25e44 eight studies used the medical record, 45e52 and in one study the method was unclear. 53 Five symptoms (fatigue, pain, lack of energy, weakness, and appetite loss) occurred in more than 50% of the patients of Group 1. Large 95% CIs (>20%) were seen for lack of energy, weight loss, dry mouth, worrying, anxiety, early satiety, and sore mouth/stomatitis.
Symptom Prevalence in Group 2
One study used a questionnaire, 54 four studies used a standardized interview, 26,32e34,55 and one study used the medical record. 46 Twenty-six of the 37 symptoms from Group 1 were assessed in at least one study for Group 2 (range: 1e6). Four symptoms (fatigue, weight loss, weakness, and appetite loss) occurred in >50% of patients. Large 95% CIs (>20%) were seen for most of the symptoms. Weight loss occurred significantly more often in Group 2 compared to Group 1, and pain, nausea, and urinary symptoms occurred significantly less often (Table 3 and Appendix 2).
Symptom Prevalence by Assessment Method, Gender, Age, and Diagnosis
For 26 symptoms, different assessment methods could be compared (Table 4) . Significant differences in mean percentages were found for dry mouth, insomnia, depressed mood, taste changes, confusion, and pruritis. For all these symptoms, the highest mean percentages were found if the symptom was assessed by means of a questionnaire.
Six studies looked at gender differences in symptom prevalence.
9,11,14,15,30, 44 Only one study corrected for diagnosis. 44 A clear indication for gender differences, occurring in most or all studies looking at that particular symptom, was found for dysphagia and insomnia (both more prevalent in men) and for nausea and vomiting (more prevalent in women).
The relation between age and symptom prevalence was investigated in four studies. 11, 16, 44, 45 No study corrected for diagnosis. An indication for age differences, occurring in at least two of the studies, was found for pain and dysphagia, both decreasing with age.
Discussion
Many studies have addressed symptom prevalence in advanced cancer patients. However, almost all studies are heavily biased due to patient selection. Moreover, several studies included relatively low numbers of patients. This is the first systematic review on symptom prevalence in patients with incurable cancer. As 46 different studies and 26,223 patients were included, the estimations of symptom prevalence are likely to be as reliable as possible as the influence of sample size and selection bias is reduced as much as possible. Contrary to many systematic reviews on other topics, publication bias is unlikely to have influenced the results. There is no reason to presume that studies on symptom prevalence have not been published because of uninteresting or ''negative'' results.
Thirty-seven symptoms (assessed in at least five studies) were identified, almost always occurring in $10% of patients. Overall, fatigue, pain, lack of energy, weakness, and appetite loss were the most frequent symptoms, occurring in >50% of patients. During the last one to two weeks of life, fatigue, weight loss, weakness, and appetite loss occurred in more than 50% of patients.
Several aspects of this study deserve further discussion. The 95% CIs of the symptom prevalences are quite large due to the heterogeneity of the studies included and probably also due to different interpretations of these symptoms in different studies. When combining the results from different studies, we had to make choices for categorizing symptoms that were labeled differently. Although most of these choices were relatively straightforward, one may argue about some of them, in particular, about the differences between fatigue, lack of energy, and weakness; about the various terms included for anxiety and depressed mood; and about the grouping of symptoms as in mouth pain/stomatitis, cognitive, voiding, skin, and neurological symptoms. Obviously, this has an impact on the symptom prevalence figures detected in our review. Another factor that may influence symptom prevalence (and may also explain the large 95% CIs) is the assessment method. We found clear differences in the prevalence of several symptoms between studies using different methods. Although this is an indirect comparison (no study compared different methods directly), and differences are probably partly due to patient selection, there seem to be patterns in prevalence differences for certain symptoms due to assessment method. For many symptoms, the lowest prevalence was seen in studies using the medical record. This finding emphasizes the importance of standardized comprehensive assessment of symptoms in palliative care.
56,57 However, this was not (clearly) the case for all symptoms, e.g., for pain, dyspnea, nausea and vomiting, constipation, and skin problems. This probably reflects the fact that these symptoms are usually spontaneously mentioned by patients and/or are explicitly and routinely addressed by doctors and nurses. For other symptoms, studies using a questionnaire showed higher prevalence figures than those using a standardized interview. Apparently, when completing a questionnaire, patients have more time and/or feel more free to indicate the presence of some symptoms that are less often mentioned during a standardized interview. Questionnaires may pick up symptoms that are not considered to be important and/or treatable by patients, doctors, and nurses, and thus are not addressed by standardized interviews or a routine history.
56,57
As there is some evidence of a final common clinical pathway in patients nearing death, 55 we separately looked at symptom prevalence in patients during the last one to two weeks of life. As only six such studies were included, and these studies varied greatly with regard to the number of patients included and symptoms assessed, the estimations are less reliable, and comparison with the overall population of incurable cancer patients is difficult. A significant increase was found for weight loss and a significant decrease for pain, nausea, and urinary symptoms. Longitudinal studies are needed to test the hypothesis that symptoms change and are less dependent on diagnosis as the end approaches. A limitation of our study is the lack of availability of individual patient data. Therefore, we were unable to assess reliably the influence of gender and age on symptom prevalence. In the limited amount of studies addressing those issues, there seemed to be limited relations between gender and age on the one hand and symptoms on the other hand. No definite conclusions about the presence or absence of these relationships can be drawn, and more study is necessary in this area.
In conclusion, we performed a systematic review giving the most reliable estimates possible of symptom prevalence in patients with incurable cancer. Focus on the more prevalent symptoms in these patients should guide symptom management by doctors and nurses. However, it must be emphasized that treatment should be based on symptom intensity, symptom burden, and the impact of symptoms on quality of life. This should be the subject of further studies to help doctors and nurses provide individually tailored treatment aimed at improving or maintaining quality of life of cancer patients in the last period of their lives. 
